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Abstract: Non-collagenous α3 chain of type IV collagen or α3(IV)NC1, a 28 kDa C-terminal domain of collagen type IV 
is a speciﬁ  c inhibitor of endothelial cell translation and angiogenesis. In the present study we have cloned and expressed 
mouse α3(IV)NC1 in baculovirus system. The recombinant protein was expressed in soluble form and tested for several of 
its biological functions. We identiﬁ  ed that this recombinant mouse α3(IV)NC1 speciﬁ  cally inhibited proliferation, transla-
tion and tube formation of endothelial cells. Also, we show that α3(IV)NC1 treatment results in apoptosis speciﬁ  cally in 
proliferating endothelial cells. In addition we report for the ﬁ  rst time that mouse α3(IV)NC1 inhibits migration and p38 
MAPK phosphorylation in addition to inhibition of FAK/Akt/mTOR/4E-BP1 signaling. In mice α3(IV)NC1 treatment 
reduced tumor growth and CD-31 positive endothelial vasculature in tumors. Collectively, our data demonstrate the expres-
sion of biologically active form of mouse α3(IV)NC1 in Sf-9 cells and provide important mechanistic insights on α3(IV)NC1 
antiangiogenic actions in endothelial cells.
Keywords: α3(IV)NC1, non-collagenous α3 chain of type IV collagen; AcNPV, Autographa californica nuclear polyhe-
drosis virus; Sf-9, Spodoptera frugiperda; MLEC, mouse lung endothelial cells; HUVEC, human umbilical vein endothelial 
cells; FCS, fetal calf serum; PMSF, Phenylmethylsulfonyl Fluoride; TNF-α, tumor necrosis factor alpha; DEVD, cell mem-
brane permeable caspase inhibitor; NC, negative control; PC, positive control; FN, ﬁ  bronectin, MAPK, mitogen activated 
protein kinase; FAK, focal adhesion kinase; PKB/Akt, protein kinase B; mTOR, mammalian target of rapamycin; 4E-BP1, 
eukaryotic initiation factor 4E-binding protein
Introduction
The non-collagenous domain from the carboxy terminal region of α3 chain type IV collagen (α3(IV)NC1 
or tumstatin), a speciﬁ  c inhibitor of endothelial cell proliferation and angiogenesis, was cloned as 28 kDa 
protein (Boosani and Sudhakr, 2007; Feng et al. 1994; Mariyama et al. 1994; Petitclerc et al. 2000). We 
have reported recently that human α3(IV)NC1 binds to α3β1/αVβ3 integrins and inhibits hypoxic cyclo-
oxygenase-2 (COX-2) signaling leading to inhibition of tumor angiogenesis and tumor growth in mice 
(Boosani et al. 2007). The serum levels of circulating mouse α3(IV)NC1 was shown around 300 ng/ml, 
where as human endostatin was in a range between 120–300 ng/ml (Dhanabal et al. 1999; Hamano et al. 
2003). The expression levels of human α3(IV)NC1 in mammalian system was reported to be very low 
(1–2 mg/liter) (Neilson et al. 1993). Based on our experience with these domains used in murine tumor 
studies, the amount of α3(IV)NC1 needed for preclinical use could not be obtained by mammalian expres-
sion system. Earlier researchers have cloned murine α3(IV)NC1 however, there was no clear evidence 
on its in vitro and in vivo functional characterization (Miner and Sanes, 1994). However, there was no 
clear evidence on its in vitro and in vivo functional characterization. We therefore cloned and expressed 
mouse α3(IV)NC1 using baculovirus expression system, in a manner similar to our recently reported work 
using human α1(IV)NC1(Boosani and Sudhakar, 2006).
In the present study, to understand biological functions of mouse α3(IV)NC1, the protein domain was 
cloned and expressed in Sf-9 cells using the baculovirus expression system. The recombinant puriﬁ  ed 
α3(IV)NC1 protein was found biologically active both in vitro and in vivo, as it inhibited endothelial cell 
proliferation and translation similar to human α3(IV)NC1. We show for the ﬁ  rst time that mouse α3(IV)NC1 74
Boosani and Sudhakar
Clinical Medicine: Oncology 2008:2 
speciﬁ  cally inhibits endothelial cell migration and 
p38 MAPK phosphorylation in addition to inhibition 
of FAK/Akt/mTOR phosphorylation.
Materials and Methods
Human umbilical vein endothelial cells (HUVEC) 
purchased from Clonetech
TM Inc; Martigel
TM 
Martix (14.6 mg/ml) was purchased from BD Bio-
sciences Discovery lab. Recombinant human bFGF 
was purchased from R&D systems. Horseradish 
peroxidase (HRP)-labeled secondary antibodies, 
penicillin/streptomycin, ﬁ  bronectin (FN), low melt-
ing Agarose and neutral red staining solutions were 
purchased from Sigma-Aldrich. Graces insect cell 
culture medium, cell ﬁ  xer and H&E staining were 
purchased form Fisher Scientiﬁ  c Inc. Baculovirus 
transfer vector pAcHLT-A, transfection reagent and  
Afﬁ  nity matrix (Ni-NTA Agarose) were purchased 
from PharMingen, USA. Caspase3 inhibitor DEVD 
was purchased from Chemicon; Protease solutions 
were purchased from Boehringer and Mannheim, 
GmbH. FCS, ECL Kit, Random primer labeling 
kit, hybond N
+ membrane, (α-
32P) dCTP, DNA 
ladder, competent DH5α cells, DNA polymerase 
1, klenow fragment and Multiprime DNA labeling 
system were purchased from Amersham Biosci-
ences. SuperScript one-step RT-PCR system and 
Lipofectamine Plus reagent obtained from Invitro-
gen. Restriction enzymes and Pfx polymerase were  
purchased from New England Biolabs.
Cell Culture
Primary HUVECs were maintained in EGM-2 
medium at 37 °C in a humidiﬁ  ed 5% CO2. Sf-9 cells 
were maintained in Graces medium supplemented 
with 10% FCS and 100 µg/ml antibiotic and 
antimycotic solution, and mouse lung endothelial cells 
were prepared and maintained as described previously 
(Boosani et al. 2007; Boosani and Sudhakar, 2006; 
Sudhakar et al. 2000). Sf-9 insect cells were grown as 
monolayer cultures and maintained at 27 °C in 
complete medium. Only cells with greater than 95% 
viability were used for expression studies.
Cloning, Expression and 
Puriﬁ  cation of Mouse α3(IV)NC1 
in Sf-9 Cells
The sequence encoding mouse α3(IV)NC1 was 
PCR ampliﬁ  ed using total RNA isolated from 129 
Sv mouse kidney and SuperScript One-Step RT-
PCR system supplemented with Pfx polymerase 
5 units per reaction. The forward primer (5′- 
CGACATATGTCCTGGTGACAGGGGAACG 
-3′) and reverse primer (5′- TCTAGATCTCCAT-
GTCTTTTCTTCATGCACACCT -3′) sequences 
were modiﬁ  ed to incorporate Nde I and Bgl II 
restriction sites and were used to amplify a 720 
bp encoding 240 amino acid sequence corre-
sponding to α3(IV)NC1. PCR ampliﬁ  cation was 
performed in PTC-100 Programmable Thermal 
Controller from MJ Research Inc, following the 
instructions in RT-PCR manual. The resulting 
amplicon was cloned into pBSIISKP vector at 
EcoR V site and the recombinant clones were 
identiﬁ  ed by blue white selection. The clones 
were sequenced using T7 and T3 promoter prim-
ers (Table 1). The sequence conﬁ  rmed clone was 
digested with Nde I and Bgl II to release the cod-
ing sequence corresponding to α3(IV)NC1. The 
released fragment was ligated into pAcHLT-A 
transfer vector (PharMingen) that was predigested 
with the same restriction enzymes, to generate 
recombinant viral transfer vector pAcHLT-A/
α3(IV)NC1 that was used for co-transfection of 
Sf-9 cells.
Co-Transfection of Sf-9 Cells
Sf-9 cells were co-transfected with pAcHLT-A/
α3(IV)NC1 viral transfer vector and linearized 
Baculogold
TM (Cat No: 21100D) viral DNA to 
obtain an infectious complete viral genome as 
reported earlier (Sudhakar et al. 2000; Boosani and 
Sudhakar, 2006).
Plaque Assay and Ampliﬁ  cation 
of Recombinant Virus
Plaque assay was carried out to identify recombinant 
virus in lysed co-transfected Sf-9 cells. Sf-9 cells 
were seeded at 1.8 × 10
6 cells per 35 mm tissue 
culture dish. Several dilutions of recombinant virus 
ranging from 10
−1 to 10
−7 were made in 100 µl of 
complete medium and known viral dilution was 
added to each petridish and incubated at 27 °C for 
1 hr with gentle rocking as reported previously by 
us (Sudhakar et al. 1999). Plaques were scored under 
a light microscope and the efﬁ  ciency of the viral 
titer in terms of plaque forming units (pfu) was 
calculated: pfu/ml = Average No. of plaques X 1/ml 
of inoculums per plate X 1/dilution factor, as 75
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described previously (Boosani and Sudhakar, 
2006).
Dot-Blot Hybridization
Brieﬂ  y, dot-blot hybridization was performed to 
identify the recombinant virus in which the 720 
bp mouse α3(IV)NC1 cDNA has been incorpo-
rated into the viral genome. The radioactive probe 
corresponding to the α3(IV)NC1 was prepared 
and used to detect positive plaques with recombi-
nant infectious virus. About 10
5 Sf-9 cells in 100 µl 
of medium were seeded into each well of a 96 well 
plate. One negative control with wild type virus 
(non-recombinant) and a positive control with the 
insert (template for the probe) were used as 
reported previously (Boosani and Sudhakar, 
2006).
Sf-9 Cells Infection and Expression 
of Mouse α3(IV)NC1
Brieﬂ  y, 4 × 10
6 cells were seeded in T-25 tissue-
culture ﬂ  ask and the cells were infected with about 
1.6 × 10
8 pfu/ml of α3(IV)NC1 viral titer for 
about 0–72 hrs. At each time point cells were 
washed with PBS and lysed in 200 µl of lysis 
buffer (20 mM Tris-HCl pH 7.8, 1 mM Mg
2+, 
1 mM DDT, pepstatin A (1 µg/ml), leupeptin (1 
µg/ml), aprotinin (1 µg/ml) and PMSF 1 µM). 
After centrifugation at 13,000 rpm for 30 min, 
the clear cytosolic extracts were used for protein 
puriﬁ  cation as described previously (Boosani and 
Sudhakar, 2006).
Metal Afﬁ  nity Puriﬁ  cation of Mouse 
α3(IV)NC1
Recombinant mouse α3(IV)NC1 protein with 
6xHis tag was expressed in Sf-9 cells and cell lysate 
∼7 ml per batch (30 to 40 mg) was mixed with 1 
ml of Ni-NTA Agarose afﬁ  nity matrix. The extract 
and Ni-NTA Agarose was incubated for 1 hr at 4 °C 
on rocker and then centrifuged at 500 × g for 5 min 
at 4 °C. The supernatant was discarded and the 
6xHis-tagged α3(IV)NC1 was eluted from the 
affinity matrix similar to our earlier reports 
(Boosani and Sudhakar, 2006). The fusion His tag 
was proteolytically cleaved from the recombinant 
protein at the thrombin cleavage site located 
upstream to the α3(IV)NC1 coding sequence. 
Recombinant mouse α3(IV)NC1 protein eluted 
from the affinity matrix was concentrated by 
0%–80% ammonium sulphate fractionation, 
1   P  G  D  R  G  T  P  A  T  G  T  R  M  R  G  F  I  F  T  R  
1   cctggtgacaggggaacgccggccactggtacaagaatgcgaggcttcatcttcacccga 
21  H  S  Q  T  T  A  I  P  S  C  P  E  G  T  Q  P  L  Y  S  G   
61  cacagtcaaaccacggccattccttcatgccctgaaggaacacagccactctatagtggg 
41  F  S  L  L  F  V  Q  G  N  K  R  A  H  G  Q  D  L  G  T  L   
121 ttttctcttctttttgtacaaggaaacaaacgtgcacatggacaagacctaggtactctg 
61  G  S  C  L  Q  R  F  T  T  M  P  F  L  F  C  N  I  N  N  V   
181 ggcagctgcctgcagcgattcaccacaatgccgttcttattctgtaacatcaataatgta 
81  C  N  F  A  S  R  N  D  Y  S  Y  W  L  S  T  P  A  L  M  P   
241 tgtaactttgcatcacgaaatgattattcatactggctgtcaacaccagctctgatgcca 
101 M  D  M  A  P  I  S  G  R  A  L  E  P  Y  I  S  R  C  T  V   
301 atggacatggctccaattagtggcagagctctcgaaccctatattagcagatgcaccgtc 
121 C  E  G  P  A  M  A  I  A  V  H  S  Q  T  T  A  I  P  P  C   
361 tgtgaaggtccagcaatggccatagctgttcacagtcaaactactgctatccctccgtgt 
141 P  Q  D  W  V  S  L  W  K  G  F  S  F  I  M  F  T  S  A  G   
421 ccccaggactgggtttctctctggaaaggtttttctttcattatgttcacaagtgcaggc 
161 S  E  G  A  G  Q  A  L  A  S  P  G  S  C  L  E  E  F  R  A   
481 tctgagggtgctggacaagcacttgcctcgcctggctcctgcctggaagaattccgagcc 
181 S  P  F  I  E  C  H  G  R  G  T  C  N  Y  Y  S  N  S  Y  S   
541 agtccatttatagaatgccatggacgagggacatgtaactactactcaaactcctacagt 
201 F  W  L  A  S  L  N  P  E  R  M  F  R  K  P  I  P  S  T  V   
601 ttctggctggcttcgctgaacccagaaagaatgttcagaaaacctattccatcaactgtg 
221 K  A  G  D  L  E  K  I  I  S  R  C  Q  V  C  M  K  K  R  H   
661 aaagctggagacttagagaaaatcataagccgctgtcaggtgtgcatgaagaaaagacat
Table 1. Mouse a3(IV)NC1 sequence (720 bp)76
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dialyzed against PBS and protein estimation was 
carried out using the Bio-Rad protein assay kit.
Endothelial Cell Proliferation
A suspension of about 5.0 × 10
4 HUVECs or MLEC 
cells/well, in a 24 well plate were used in prolifera-
tion assay. Cells were serum starved overnight and 
transferred to 24 well plates pre-coated with 
ﬁ  bronectin and cultured for 24 hr in EGM-2 medium 
containing various concentrations of mouse 
α3(IV)NC1. After 24 hr, 1 µI of [
3H]-thymidine was 
added into each well and further incubated at 37 
°C 
for 24 hrs. Cell proliferation was assessed by study-
ing the incorporation of [
3H]-thymidine that was 
measured using scintillation counter as described 
previously (Sudhakar et al. 2005).
Endothelial Cells Protein Synthesis
To study the effects on translation, protein synthesis 
in serum starved HUVECs or MLEC cells were 
studied. The cells were pre-incubated in methionine-
free media for 1 hr and then labeled with radioactive 
methionine and further incubated for one more hour. 
The incorporation of radioactivity into trichloroacetic 
acid precipitates was analyzed after 48 hrs as 
described previously (Maeshima et al. 2002). 
ANOVA with a one tailed student’s t test was used 
to identify significant differences in multiple 
comparisons where p   0.01 was considered 
statistically signiﬁ  cant.
3-(4,5-Dimethylthiazol-2-yl)-2,5-
Diphenyl Tetrazoliumbromide 
Assay (MTT) for Apoptosis
HUVECs or MLEC cells (8000 cells/well) were 
plated on a 96-well plate in EGM-2 medium. After 
24 hrs, varying concentrations of α3(IV)NC1 was 
added and further incubated for 24 h. Cell viability 
was assessed by 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyl tetrazoliumbromide assay (MTT), as 
described previously (Boosani and Sudhakar, 
2006).
Migration Assay
About 10,000 HUVECs or MLEC cells in 30 µl of 
incomplete medium (ICM) with and without 
recombinant α3(IV)NC1 (1 µM) were seeded into 
each upper well of the Boyden chamber. In the 
lower wells of Boyden chamber, ICM containing 
25 ng/ml bFGF was added and incubated for 24 hr 
at 37 °C with 5% CO2. ICM alone was used as 
negative control (data not shown). The number of 
cells that migrated and attached to the bottom side 
of the membrane were counted as described previ-
ously (Boosani et al. 2007; Sudhakar et al. 
2005).
Tube Formation Assay
About 250 µl of matrigel-matrix was added to each 
well of a chilled 24 well plate and the matrix was 
allowed to polymerize for 30 min at 37 °C. A sus-
pension of 5 × 10
4 HUVECs or MLEC cells in 
EGM-2 without antibiotic were plated on top of 
the matrigel-matrix. Cells were treated with or 
without 1.0 µM α3(IV)NC1 and incubated for 
48 hr at 37 °C, and the tube formation was observed 
using a CK2 Olympus microscope as reported 
earlier (Boosani et al. 2007; Sudhakar et al. 2005). 
All assays were performed in quadruplicates.
Cell Signaling Experiments
About 10
6 HUVECs or MLEC cells were seeded 
on a 10 cm
2 petridish coated with fibronectin 
(10 µg/ml). The monolayer cell culture was pre-
incubated with mouse α3(IV)NC1 or human end-
ostatin and the cells were lysed with 200 µl of lysis 
buffer. The cell extracts were separated on a 10% 
SDS-PAGE and transferred onto a nitrocellulose 
membrane by western blotting. The signaling 
events were evaluated following immunoblotting 
using antibodies speciﬁ  c to phosphorylated and 
unphosphorylated proteins as described previously 
(Boosani et al. 2007; Sudhakar et al. 2005).
In vitro Kinase Assay for mTOR 
Activity
Phosphorylation of mTOR and GST-4EBP-1 
fusion protein (mTOR substrate) was evaluated in 
HUVECs or MLEC cells transfected with HA-
mTOR/FRAP expression plasmid as described 
previously (Maeshima et al. 2002; Sudhakar et al. 
2003). Brieﬂ  y, cells were serum starved and tran-
siently transfected with HA-mTOR/FRAP plasmid 
using Lipofectamine Plus reagent (Invitrogen, 
Carlsbad, CA). About 4 × 10
6 transfected cells were 
treated with mouse α3(IV)NC1 and human end-
ostatin (1 µM) for 24 hours according to the 77
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experimental protocol. The cells were lysed and 
200 µg of extracts were subjected to immunopre-
cipitation with anti-HA antibody. HA-mTOR/Anti-
HA complexes were incubated with recombinant 
GST-4E-BP1 fusion protein in presence of 10 µCi 
of [γ
32P]-ATP in kinase buffer. The reactions were 
terminated by boiling, and the samples were sub-
jected to SDS-PAGE. The phosphorylated proteins 
of mTOR-P and GST-4EBP1-P were detected by 
autoradiography.
Results
Expression and puriﬁ  cation of mouse 
α3(IV)NC1 using baculovirus 
expression system
The sequence encoding mouse α3(IV)NC1 (720 
bp) was ampliﬁ  ed from 129 Sv mice kidney total 
RNA. The sequence was conﬁ  rmed using high-
throughput DNA sequencing facility at University 
of Nebraska Medical Centre, followed by a BLAST 
search that matched both the strands completely 
with published sequence of mouse collagen Type 
IV (Miner and Sanes, 1994). Comparing the mouse 
and human α3(IV)NC1 protein sequences showed 
91% similarity at amino acid level, demonstrating 
a high degree of homology between them (mouse 
α3(V)NC1 sequence ACC number NM 007734 Vs 
human α3(V)NC1 sequence ACC number NM 
000091).
The sequence encoding mouse α3(IV)NC1 was 
cloned into baculovirus transfer vector pAcHLT-A 
between Nde I and Bgl II restriction sites. The 
resulting recombinant baculovirus transfer vector 
pAcHLT-A/α3(IV)NC1 has the 6xHis tag located 
upstream to α3(IV)NC1 to enable one-step puriﬁ  -
cation using afﬁ  nity chromatography. The recom-
binant baculovirus viral transfer vector 
pAcHLT-A/α3(IV)NC1 was co-transfected with 
linearized BaculoGold
TM Baculovirus DNA to 
obtain an infectious virus as reported previously 
(Boosani and Sudhakar, 2006). To conﬁ  rm the 
infectious complete viral genome harboring 
α3(IV)NC1, a radioactive probe corresponding to 
mouse α3(IV)NC1 cDNA was used to identify the 
recombinant plaques (Fig. 1A). Six out of 18 
plaques used for α3(IV)NC1 were found positive 
(Fig. 1A lanes 1, 2 and 3 a, b). The supernatants of 
the positive plaques from the 96 wells were used 
for further amplification and expression as 
described previously (Boosani and Sudhakar, 2006; 
Sudhakar et al. 2000).
Sf-9 cells were co-transfected with recombinant 
virus (MOI-10) harboring pAcHLT-A/α3(IV)NC1 
and extracts were prepared at different time points 
of post-infection. Mouse α3(IV)NC1 was expressed 
as a 28 kDa soluble protein whose concentration 
increased with increase in post-infection time up 
to 72 hrs (Fig. 1B, lanes 2 to 5). Wild type AcNPV 
virus infected cells did not produce any protein of 
similar molecular mass (data not shown). The over 
expressed α3(IV)NC1 protein cross reacted with 
anti-α3(IV)NC1 antibody as observed through 
western immunoblotting (Fig. 1B lower panel). 
The puriﬁ  cation proﬁ  le of mouse α3(IV)NC1 using 
single step afﬁ  nity matrix chromatography was 
carried out as described earlier (Boosani and 
Sudhakar, 2006) (Fig. 1C). After dialysis from the 
single step puriﬁ  cation, the levels of expression 
was measured using BCA assay.
Mouse α3(IV)NC1 has translation 
inhibition and anti-proliferative effects 
on endothelial cells
HUVECs or MLEC cells showed reproducible 
translation and proliferation inhibition response for 
human α3(IV)NC1 (Maeshima et al. 2002). We 
Figure 1. Cloning, expression and purification of mouse 
α3(IV)NC1.
Panel A. Dot-blot analysis of the plaques containing recombinant 
virus expressing α3(IV)NC1: Plaques (a and b) lanes 1, 2 and 3 were 
found to be positive. The wells c and d (1 and 2) serve as negative 
controls containing non-recombinant AcNPV virus infected cell 
extracts, and well e (1, 2 and 3) corresponds to un-infected Sf9 cell 
extracts serves as negative control. α3(IV)NC1 cDNA was used as 
positive control in lane 3 (c and d). Panel B. Time course expression 
of α3(IV)NC1 in Sf9 insect cells at 12, 24, 48 and 72 hr of post infec-
tion: Lane 1 shows uninfected cell extracts at 0 hr (control). Each 
lane contains about 30 µg of crude cell extract and the ﬁ  gure is a 
coomassie-stained gel. Western immunoblot analysis of the time 
course expression of α3(IV)NC1 using α3(IV)NC1 antibody are shown 
in lower Panel. Panel C. Puriﬁ  cation of α3(IV)NC1 using afﬁ  nity 
matrix: Lane 1 shows 10 µg of ﬂ  ow through, lanes 2 and 3 shows 
1 µg of afﬁ  nity puriﬁ  ed α3(IV)NC1 before and after dialysis.78
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initially used these cells to examine the translation 
inhibitory action and anti-proliferative effects of 
mouse α3(IV)NC1. As expected, we observed dose 
dependent inhibitory effect on protein synthesis in 
endothelial cells upon mouse α3(IV)NC1 treatment. 
About 2 µM concentration of mouse α3(IV)NC1 
showed 50% inhibition of protein synthesis 
(Fig. 2A). Similar inhibition of protein synthesis 
was also reported previously using human 
α3(IV)NC1 (Maeshima et al. 2002). These results 
conform that mouse α3(IV)NC1 shows protein 
synthesis inhibition similar to human α3(IV)NC1. 
Further we also observed dose dependent inhibition 
of proliferation upon mouse α3(IV)NC1 treatment 
to endothelial cells (Fig. 2B). Interestingly, mouse 
α3(IV)NC1 did not show any effect on translation 
or proliferation of human 789-0 renal cell carcinoma 
and LLC cells (data not shown).
Induction of apoptosis in endothelial 
cells by mouse α3(IV)NC1
In order to understand the mechanism of action of 
mouse α3(IV)NC1 on endothelial cells, ﬁ  rst we 
studied whether the inhibitory action in endothelial 
cells was due to its effect on cell viability, and thus 
treated HUVEC or MLEC cells with different 
concentrations of mouse α3(IV)NC1. A dose 
dependent cell death was observed with increasing 
concentrations of mouse α3(IV)NC1 treatment 
(Fig. 2C). To further understand the endothelial 
cell death mediated signaling by α3(IV)NC1, we 
carried out caspase-3 activation assays. Caspase-3 
is an intracellular protease activated at the early 
stages of apoptosis and initiates cellular breakdown 
by degrading structural and DNA repair proteins 
(Magnon et al. 2005). The caspase-3 activity was 
measured spectrophotometrically through the 
detection of chromophore (p-nitroanilide) cleaved 
from the labeled substrate (DEVD-p-nitroanilide) 
upon α3(IV)NC1 treatment in endothelial cells. 
α3(IV)NC1 treated endothelial cells exhibited a 4 
fold increase in caspase-3 activity, whereas TNF-α 
a known caspase-3 activator treatment gave 4.6 
fold increase of caspase-3 activity compared to 
control (Fig. 2D). A speciﬁ  c inhibitor of caspase-3, 
DEVD, decreased caspase-3 activity to baseline 
indicating that the increase in the measured activ-
ity was speciﬁ  c for caspase-3. These results sug-
gests that one of the mechanisms by which mouse 
α3(IV)NC1 affects cell proliferation is through 
caspase-3 activation.
Antiangiogenic effects of mouse 
α3(IV)NC1
Next we utilized mouse α3(IV)NC1 protein to test 
the migratory effect on HUVECs or MELC cells 
across ﬁ  bronectin coated membrane towards bFGF 
in a Boyden chamber. Surprisingly, we identiﬁ  ed 
the anti-migratory effect of mouse α3(IV)NC1 
similar to other collagen NC1 domain which we 
have previously reported (Sudhakar et al. 2005) 
(Fig. 3A). These results supports that mouse 
Figure 2. Functional characterization of mouse α3(IV)NC1.
Panel A. The graph summarizes results from three independent 
protein synthesis experiments on the relative uptake of radioactive 
[
35S] methionine at 48 hrs of α3(IV)NC1 treatment. *Indicates 
P   0.03 (1 µM α3(IV)NC1 treatment compared to FCS. **Indicates 
P   0.01 (rapamycin treatment compared to FCS). Panel B. The 
graph summarizes results from three independent proliferation 
experiments on the relative uptake of [
3H]-thymidine incorporation. 
*Indicates P   0.01 (1 µM α3(IV)NC1 treatment compared to FCS. 
**Indicates P   0.005 (1 µM α1(IV)NC1 treatment compared to FCS). 
Panel C. Cell Viability assay: The 3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyl tetrazoliumbromide assay (MTT) was used to evaluate 
HUVECs or MLEC cells viability after treatment with α3(IV)NC1. 
α3(IV)NC1 decreased the cell viability in a dose-dependent manner. 
*Indicates P   0.005 (with and without 1 µM α3(IV)NC1 treatment. 
Panel D. Control and α3(IV)NC1 treated cells were lysed, and 
caspase-3 activity was detected. DEVD and TNF-α were used as 
positive controls. *Indicates P   0.005 (TNF-α alone or with TNF-α 
with DEVD treatment. In panel A-C −FCS and +FCS represents cells 
grown in 0.1% and 10% FCS medium.79
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α3(IV)NC1 is capable of inhibiting endothelial 
cell migration, where as human molecule is not 
(Boosani et al. 2003). Our results, suggests that 
mouse α3(IV)NC1 is a more potent anti-angiogenic 
molecule compared to human α3(IV)NC1. 
In addition antiangiogenic activity of mouse 
α3(IV)NC1 was confirmed by tube formation 
assay. Addition of mouse α3(IV)NC1 protein to 
the endothelial cell culture media signiﬁ  cantly 
inhibited tube formation on matrigel matrix 
(Fig. 3B). Our earlier reports also indicate that 
human α3(IV)NC1 inhibits tube formation in 
endothelial cells (Boosani et al. 2007; Sudhakar et 
al. 2003).
Signal transduction cascades induced 
by recombinant mouse α3(IV)NC1
Finally, the characteristic antiangiogenic activity 
of mouse α3(IV)NC1 was conﬁ  rmed by integrin 
mediated cell signaling experiments. In endothelial 
cells, ligand upon binding to integrins induces 
phosphorylation of focal adhesion kinase (FAK), 
which serves as a platform for different down-
stream signals (Zachary and Rozengurt, 1992). 
Recombinant mouse α3(IV)NC1 inhibited phos-
phorylation of FAK when endothelial cells were 
cultured on ﬁ  bronectin (Fig. 3C). Downstream to 
FAK, protein kinase B (PKB/Akt), phosphatidyl-
3-kinase (PI3 kinase) plays an important role in 
mediating pathways that are involved in the 
regulation of endothelial cell survival (Maeshima 
et al. 2002; Shiojima and Walsh, 2002; Sudhakar 
et al. 2003). Akt was also known to regulate protein 
synthesis mediated by phosphorylation of 
eukaryotic initiation factor 4E-binding protein 
(4E-BP1) via mTOR kinase (Miron et al. 2001). 
Our studies show that mouse α3(IV)NC1 inhib-
ited sustained phosphorylation of Akt activation 
and p38 MAP kinase in HUVECs or MLEC cells 
that are plated on ﬁ  bronectin (Fig. 3, D and E). 
Downstream to Akt, mTOR directly phosphory-
lates eIF4E-binding protein (4E-BP1) and unphos-
phorylated 4E-BP1 interacts with eIF4E and inhib-
its cap-dependent protein synthesis (Maeshima et 
al. 2002; Pause et al. 1994; Sudhakar et al. 2003). 
Recombinant mouse α3(IV)NC1 suppressed 
mTOR activity and inhibited phosphorylation of 
4E-BP1 in endothelial cells similar to human 
α3(IV)NC1 (Fig. 3F). Inhibition of 4E-BP-1 phos-
phorylation enhanced binding to eIF-4E, which in 
turn becomes unavailable to initiate cap-dependent 
translation (Fig. 3F, lower blot).
Effect of α3(IV)NC1 on SCC-PSA1 
tumor growth and endothelial cell 
apoptosis
We examined the effect of mouse α3(IV)NC1 on 
SCC-PSA1 (teratocarcinoma) tumor models in 
129Sv mice. Treatment of mouse α3(IV)NC1 at 
30 µg concentration showed signiﬁ  cant inhibitory 
Figure 3. Cell signaling experiments with mouse α3(IV)NC1.
Panel A. Migration of HUVECs or MLEC cells with and without mouse 
α3(IV)NC1. Panel B. Tube formation of endothelial cells on Matrigel 
matrix with and without α3(IV)NC1. Migration and tube formation of 
endothelial were viewed using a light microscope at 100x magniﬁ  ca-
tion. Panel C-E. Serum-starved HUVEC or MLEC cells were plated 
on ﬁ  bronectin coated culture plate supplemented with 1 µ α3(IV)NC1 
for the indicated times and cytosolic extracts were analyzed by 
western blotting. Immunoblots of phosphorylated FAK or Akt or p38 
(top blot) and total FAK or Akt of p38 (lower blot) were shown. Panel 
F. mTOR kinase Assay: Autoradiograph of the autophosphorylated 
mTOR (top blot) and phosphorylated 4E-BP1 (lower) isolated from 
(HA)-mTOR transfected HUVECs shown. (P) and FN represents 
phosphorylated protein and ﬁ  bronectin.80
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effect on SCC-PSA1 tumor growth similar to 
human α3(IV)NC1 recently reported by us 
(Fig. 4A) (Boosani et al. 2007). The number of 
CD-31 positive blood vessels in α3(IV)NC1 
treated tumors were signiﬁ  cantly inhibited com-
pared to control tumors (Fig. 4B).
Collectively, our results suggested that baculovi-
rus expressed mouse α3(IV)NC1 inhibits FAK/Akt 
activation and leads to inhibition of p38/mTOR/4E-
BP1 and cap-dependent translation with signiﬁ  cant 
effect on migration, whereas human α3(IV)NC1 did 
not show any effect on endothelial cell migration and 
p38 MAPK phosphorylation. Further analysis of this 
molecule and its role in antiangiogenesis and cancer 
needs extensive evaluation.
Discussion
A number of endogenous, endothelial cell-speciﬁ  c 
angiogenesis inhibitors have been identiﬁ  ed and 
were functionally characterized both in vitro and in 
vivo. Many of these molecules were found to be 
shorter fragments of large parent molecules 
generated by proteases and gaining new properties. 
For example, endostatin and several type IV collagen 
non-collagenous (NC1) domains show antiangio-
genic activities (O’Reilly et al. 1997; Petitclerc et 
al. 2000). Among type IV collagen NC1 domains, 
α3(IV)NC1 is extensively studied for its anti-angio-
genic activity (Boosani et al. 2007; Borza et al. 2006; 
Maeshima et al. 2002; Petitclerc et al. 2000). Mouse 
α3(IV)NC1 was found inhibiting endothelial cell 
migration and proliferation, where as human 
α3(IV)NC1 is inhibiting endothelial proliferation 
but not migration (Sudhakar et al. 2003). Therefore 
large scale production of soluble mouse α3(IV)NC1 
is needed to better understand its in vivo mechanism 
(s) of action and for its potential therapeutic use.
In this study, we demonstrate for the ﬁ  rst time 
that biologically active mouse α3(IV)NC1, can be 
expressed in Sf-9 cells using baculovirus expres-
sion system. Mouse α3(IV)NC1 was expressed as 
a soluble form (28 kDa) and puriﬁ  ed using single 
step protocol (Boosani and Sudhakar, 2006). The 
yield was signiﬁ  cantly improved compared to 
human α3(IV)NC1 in 293 human kidney cells and 
the puriﬁ  cation process was very economical. 
However, in the baculovirus system several factors 
signiﬁ  cantly improve the yield ( 2 to 3 fold) of 
expressed proteins such as viral titer, cell viability, 
temperature etc. Using a similar baculovirus 
expression system we recently demonstrated efﬁ  -
cient production of human α1(IV)NC1 (Boosani 
and Sudhakar, 2006). Baculovirus expressed 
recombinant α3(IV)NC1 protein was soluble and 
was biologically active in a variety of in vitro and 
in vivo experiments. Recombinant mouse 
α3(IV)NC1 inhibited proliferation and translation 
of HUVECs or MLEC cells similar to human 
α3(IV)NC1. Both mouse and human α3(IV)NC1 
showed similar effects on endothelial cell viability 
and apoptosis in a dose dependent manner.
Recently we reported that human α3(IV)NC1 
regulates cap dependent translation and tumor 
angiogenesis in a COX-2 dependent manner 
Figure 4. Inhibition of tumor growth and tumor angiogenesis in 
129/Sv mice.
Panel A. We injected mouse α3(IV)NC1 protein to SCC-PSA1 tumor 
bearing mice daily for 15 days. Data are representative of three such 
independent experiments. The results are shown as the mean ± SEM 
and p   0.001 compared to mice with and without α3(IV)NC1 
injection. Panel B. Frozen sections (4-µm) from tumor tissue were 
stained with anti-CD31 antibody and the number of CD31 positive 
blood vessels were counted in 6 ﬁ  elds. The blood vessel quantiﬁ  cation 
results were shown as the mean ± SEM. *Indicates p   0.001; 
compared to mice with and without mouse α3(IV)NC1 treatment. 
Scale bar corresponds to 50 µM. Arrows indicated CD31 positive 
endothelial vasculature.81
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(Boosani et al. 2007; Maeshima et al. 2002; Sudhakar 
et al. 2003). Our data supports that mouse α3(IV)NC1 
effects FAK/Akt/mTOR/4E-BP1 signaling similar 
to human NC1. Whereas mouse α3(IV)NC1 shows 
speciﬁ  c differences in functional activities compared 
to human α3(IV)NC1 such as inhibition of endothe-
lial cell migration and p38 MAPK phosphorylation 
(Table 2). Human and mouse α3(IV)NC1 share 91% 
sequence homology, whereas mouse α3(IV)NC1 
lacks RGD sequence in the N terminal end. Whether 
apoptosis and proliferation is a prerequisite for the 
cap-dependent translation inhibition by human 
α3(IV)NC1 remains to be explored. Thus the avail-
ability of this protein in its biologically active form 
in large scale (quantities) will helps further functional 
analysis of this protein.
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